The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism by unknown
Minarikova et al. Lipids in Health and Disease 2014, 13:158
http://www.lipidworld.com/content/13/1/158RESEARCH Open AccessThe effects of treatment on lipoprotein
subfractions evaluated by polyacrylamide gel
electrophoresis in patients with autoimmune
hypothyroidism and hyperthyroidism
Zuzana Minarikova1, Ludovit Gaspar1, Peter Kruzliak2*, Zuzana Celecová1,3 and Stanislav Oravec1,4Abstract
Background: Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes
development. Hypothyroidism is one of the most common causes of secondary dyslipidemias which results from
reduced LDL clearance and therefore raised levels of LDL and apoB. Association between small dense LDL (sdLDL)
presentation and thyroid status has been examinated using polyacrylamide gel electrophoresis for lipoprotein
subfractions evaluation.
Methods: 40 patients with diagnosed autoimmune hypothyroidism and 30 patients with autoimmune
hyperthyroidism were treated with thyroxine replacement or thyreo-suppressive treatment. In both groups lipid
profiles, LDL subractions, apolipoproteins (apoA1, apoB), apoA1/apoB ratio and atherogenic index of plazma (AIP)
were examined before treatment and in state of euthyreosis.
Results: Thyroxine replacement therapy significantly reduced levels of total cholesterol (TC), LDL, triglycerides (TG)
and also decreased levels of sdLDL (8,55±11,671 vs 0,83±1,693mg/dl; p<0,001), apoB and AIP. For estimation of
atherogenic lipoprotein profile existence an AIP evaluation seems to be better than apoB measurement because of
the more evident relationship with sdLDL (r=0,538; p<0,01). Thyreo-suppressive therapy significantly increased levels
of TC, LDL, TG and apoB. The sdLDL was not found in hyperthyroid patients.
Conclusions: Atherogenic lipoprotein profile was present in 52.5% of hypothyroid subjects, which is higher
prevalence than in normal, age-related population. Substitution treatment leads to an improvement of the lipid
levels, TG, apoB, AIP and LDL subclasses. It significantly changed the presentation of sdLDL – we noticed shift to
large, less atherogenic LDL particles. Significantly positive correlation between sdLDL and TAG; sdLDL and VLDL
alerts to hypertriglyceridemia as a major cardiovascular risk factor.
Keywords: Atherogenic dyslipidemia, Hypothyroidism, Small dense LDL, apoB, Atherogenic index of plasmaBackground
The relationship between small dense LDL (sdLDL) and
coronary heart disease (CHD) has been a debated issue for
a long time [1]. Many cross-sectional studies have con-
firmed the finding of Fisher et al. [2]. They first pointed
out that among patients with CHD (with premature* Correspondence: peter.kruzliak@savba.sk
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article, unless otherwise stated.atherosclerosis) “diverse” LDL are more present in com-
parison to the control group [2,3]. Results of cross-
sectional and prospective epidemiological studies point to
the fact that the predominance of sdLDL in plasma is
associated with the development of CHD [1,4,5]. This
finding has been accepted as a warning cardiovascular risk
factor by the National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATP III) [6].
Elevated levels of the sdLDL may increase the risk of
atherosclerosis in various levels of LDL. Thanks to spe-
cific properties of sdLDL predominance of sdLDL meanstral Ltd. This is an Open Access article distributed under the terms of the
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levels of LDL1 and LDL2 [7,8]. SdLDLs have easier access
to the subendothelial spaces in the arterial wall and exhibit
enhanced binding to intimal proteoglycans [7,9,10]. This
increased risk of atherogenesis may be partially due to
increased susceptibility to oxidation and glycation or to
decreased clearance becouse of reduced affinity for the
LDL receptor [7,11]. SdLDLs also exhibit increased uptake
by macrophages, therefore facilitating the formation of
foam cells [12]. Furthermore, sdLDL has slowed metabol-
ism compared to that of medium-sized LDL [13] and is
associated with an elevated fibrinogen level [14]. Finally,
an inverse relationship between LDL particle size and level
of plasminogen activator inhibitor-1, a factor associated
with impaired fibrinolysis and atherosclerotic disease [15].
This makes from sdLDL strong atherogenic lipoprotein
[5,7,16,17]. For these reasons the size determination of the
LDL particles, is an important step in cardiovascular risk
assessment, along with use of other certificated parameters.
The recent knowledge of LDL subclasses have an
impact on therapy not only primary but also secondary
dyslipidemias. Thyroid diseases, like hypothyroidism,
represent one of the most common types of secondary
dyslipidemias. The examination of lipoproteins as well
as the possibility of LDL subclasses analysis can provide
a different perspective and better evaluation of cardio-
vascular risk in these patients. There are not many
publications concerning this topic in the literature and
moreover present contradictory results. Other reports
are more focused on standard indicators of atherogen-
esis such as total cholesterol (TC), LDL cholesterol, apo-
lipoprotein B (apoB), triglycerides (TG), as on the
evaluation of LDL subclasses [18-24].
Ultimately the results suggest that decreased thyroid
function affects the size of LDL and the center of clinical
interest is again in the metabolism of triglycerides, hypertri-
glyceridemia, and their potential to shape the atherogenic
lipoprotein subpopulations [19,22]. Because of suggestions
that thyroid hormones modulate serum lipoprotein levels,
we aimed to assess the relationship between LDL particle
size (included in lipoprotein spectrum) and thyroid func-
tion changes in selected groups of patients. We decided to
evaluate a relationship between atherogenic dyslipidemia,
hypothyroidism and hyperthyroidism and the effect of
treatment on the lipoprotein spectrum in these patients.
Methods
There were two groups of participants attending the
Endokrinology outpatient clinic of 2nd Department of
Internal Medicine in University Hospital in Bratislava,
Slovakia and also the Private endocrinology outpatient
clinic of M. Podobová, MD. in ENDOTOPMED s.r.o.
Bratislava, Slovakia. In the first group forty newly diag-
nosed patients with autoimmune hypothyroidism (36women, 4 men) were included. The second group com-
prised thirty newly diagnosed patients with autoimune
hyperthyroidism (25 women, 5 men). Patients were clas-
sified as hypothyroid if serum TSH level was > 5 mIU/l
or hyperthyroid if serum TSH level was 0,5 < mIU/l, tak-
ing into consideration fT4 levels as well. The reference
range in our laboratory is: TSH (0.55-4.78 mIU/l); fT4
(11.5 – 22.7 pmol/l). Exclusion criteria were: diabetes melli-
tus, other diseases of the endocrine system, familiar hyper-
cholesterolemia, liver or renal disease, pregnant women,
patients with stroke, heart attack, cancer, pancreatitis,
alcohol abuse and use of known lipid-lowering drugs. All
patients were recruited into the study voluntarily after sign-
ing informed consent. The research proposal was approved
by the Ethical Committee of the University Hospital in
Bratislava and Faculty of Medicine of Comenius University
in Bratislava, Slovakia.
Blood samples
Blood samples were collected, from all participants sub-
jects after 12 hours overnight fasting and stored in plain
tubes. Serum was isolated after clot retraction and centri-
fugation (3500 rev/min, 15 min) and subsequently divided
into 3 aliquot parts and stored at −70°C until analysis was
performed within 1 month of sample collection. Other
tubes for biochemical analysis were immediately sent to
the laboratory for examination.
Assays
Basic laboratory biochemical examination: total choles-
terol (TC): CHOD-PAP enzymatic method (cholesterol
oxidase - 4-aminoantipyrine); triglycerides (TG), − an
enzymatic GPO-PAP method (glycerol-3-phosphate oxi-
dase - 4-aminoantipyrine); LDL cholesterol - the direct
selective enzymatic determination; HDL cholesterol -
the direct immuno-inhibitory enzymatic determination;
(Erba-Lachema, Brno, ČR).
For the thyroid function tests: TSH, fT4 - chemilumin-
escence immunoassay (LIA, Siemens); for autoantibodies
against thyroid tissue (aTg, aTPO eventually aTSHR) and
thyroglobulin (Tg) - electrochemiluminescence immuno-
assay (ECLIA, Roche).
Apolipoprotein A1 and apolipoprotein B serum were
examinated by imunoturbidimetric method (Roche,
SRN). ApoA1/apoB ratio and AIP (log (TAG/HDL chol-
esterol) were evaluated manually [25,26].
LDL subclass analysis
To identify atherogenic lipoproteins several methods
(gradient gel electrophoresis, proton magnetic resonance
spectroscopy, ultracentrifugation) have been developed.
They are, however to laborious, expensive and not appro-
priate for routine clinical use [27-30]. An alternative and
less demanding approach to LDL subclasses study is a
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been commercialized on the Lipoprint system (Quantime-
trix Corporation, USA) [31]. It is relatively simpler to op-
erate, provides particle size, allows quantitation of sdLDL
fractions and correlates with the other methods [31-33].
This method enables the analysis of 12 lipoprotein sub-
fractions: VLDL; IDL1, IDL2, IDL3 (MID C, B, A); LDL1,
LDL2 (large buoyant LDL), LDL 3–7; and HDL. Accord-
ing to LDL electrophoretic profile, 2 phenotypes can be
defined: phenotype A with normal total cholesterol mass
of the sdLDL subfractions and phenotype non-A (called
phenotype B) where total cholesterol mass of the sdLDL
subfractions is intermediate – low [11,31-35]. Atherogenic
lipoprotein profiles are characterized by a predominance
of atherogenic lipoproteins, namely very low density
(VLDL), intermediate density IDL1 and IDL2 and particu-
larly by the presence of small dense lipoproteins with low
density (LDL). These profiles identify highly atherogenic
LDL subfractions - the LDL 3–7 fractions. These
subfractions are smaller, with a diameter < 26.5 nm (265
Angström) and they float within a density range of
1.048 – 1.065 g/ml, a higher density than LDL1 and
LDL2 [7,11,17]. The cutoff for elevated cholesterol mass
of the sdLDL subfraction with this system is
0.155 mmol/l [35]. The size cutoff is above or equal to
26,8 nm for phenotype A (normal LDL size) and less
than the mentioned value for non-A (phenotype B)
[19,32]. Interpretation and determination of non-
atherogenic Type A eventually atherogenic Type B lipo-
protein spectrum is performed by software for Lipoprint
LDL system (Lipoprint LDL system, Quantimetrix
Corporation, USA) [31].
The process involves applying 25 μl of serum sample to
the „redy-to-use” polyakrylamide gel tube with 200 μl of a
loading high-resolution 3% gel solution containing a lipo-
philic dye (Sudan Black B). The dye binds to the cholesterol
in the lipoprotein particles permitting the visualization and
measurement of lipoprotein fractions after electrophoretic
separation. The photo-polymerization of sample loading gel
mixture happens at room temperature for 30 min and is
followed by electrophoresis at a constant current of 3 mA/
elfo-tube for one hour. In a series of 12 samples, one rep-
resents a control sample with a defined value of the con-
centration of lipoproteins and their subpopulations and is
part of LipoprintLDL set. When the process of electro-
phoresis is finished, tubes are left in the dark for 10 minutes.
The next step is densitometric evaluation of the tubes
(610 nm) [31].
Serum lipoprotein sub-populations (VLDL, MID A-B
(IDL 3–1), LDL 1–7, HDL) are divided on the basis of
particles size. VLDL migrates as the slowest (Rf = 0) and
can be identified on a strip at the beginning of the gel.
MID and LDL migrate between Rf = 0 and Rf = 1. HDL
particles are the smallest, migrate farthest and form aband at the forefront of the gel, Rf = 1 [31]. Gel images
are analyzed by software for Lipoprint LDL system
(Lipoprint LDL system, Quantimetrix Corporation,
USA). The bands are divided into discrete segments and
the relative area under the curve is calculated for each
lipoprotein band. Also cholesterol concentration for
each lipoprotein fraction is calculated by this program
using total cholesterol value obtained for each sample by
the method indicated previously [19,31-33].
All tested parameters were measured in both groups, in
patients with newly diagnosed autoimmune hypothyroidism
and hyperthyroidism, before treatment and also in euthyr-
eosis, after thyreo-substitution or after thyreo-suppressive
therapy.
Types of dyslipoproteinemias according to lipoprotein
phenotype
Among patients with hypothyroidism 32.5% had isolated
hypercholesterolemia, 42.5% had combined hyperlipid-
emia and 7.5%, had isolated hypertriglyceridemia. The rest
(17.5%) had normal lipids levels. Phenotype B occured in
21 participants (52.5%), which was more often in the case
of combined hyperlipidemia and hypertriglyceridemia
than in isolated hypercholesterolemia or in subjects with
normal lipid levels (Figure 1). Hyperthyroid patients did
not have hyperlipoproteinemia. Atherogenic lipoprotein
profile type B was not present in these patients. Non-
atherogenic lipoprotein profile was detected in all patients
in this group. All the participants had normal levels of
lipids.
Data analysis
Statistical analysis was performed using SPSS for
Windows 20.0 (Student’s t-test; unpaired T-test; Kolmo-
gorov – Smirnov test; Pearson corelation; Spearman
corelation; Analysis of variance (ANOVA); Kruskal –
Wallis test; Wilcoxon signed-rank test). Descriptive sta-
tistics were used to present the data. Non-parametric
statistical methods were used as the variables were not
normally distributed. P-value < 0.05 was considered as
significant.
Results
Anthropometric and demographic features of the partici-
pants are shown in Table 1. Patients with hypothyroidism
were treated with levothyroxine. The average dose of
levothyroxine was 81.25 g/day (50-150 μg). The appropri-
ate dose was necessary to be individually adjusted during
therapy. The substitution treatment lasted on average for
7.13 months (SD = ± 2.32 months, range 3–12 months).
Patients with hyperthyroidism were suppressed by the
treatment with either thiamazole (doses up to 40 mg/day)
or propylthiouracyl (doses up to 100 mg/day). The starting
dose was higher than the maintenance dose and it was
Figure 1 Phenotype A and B in hypothyroid patients. * - normal values of TC, LDL, TG; iHCH – isolated hypercholesterolemia; combined HL – combined
hyperlipidemia; iHTAG – isolated hypertriglyceridemia.
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tient. In some cases it was required to go for the combin-
ation therapy or change the treatment. Most patients were
treated with thiamazole, especially towards to the end of
the study. The therapy lasted on average of 9.35 months
(SD = ± 5.84 months, range: 2–21 months).
Correlations of plasma atherogenic markers
To find out the correlation relationship between vari-
ables, we used Pearson's correlation coefficient. Subse-
quently we used the Spearman correlation coefficient to
determine the statistical significance between non-
parametric data. The correlations between subpopula-
tions of LDL, VLDL and HDL compared with AIP, apoB
and apoA1/apoB ratio in a group of patients with
hypothyroidism are shown in Table 2. There was signifi-
cantly positive correlation between apoB and LDL3-7,
AIP and LDL3-7 and both apoB and AIP with VLDL in
hypothyroid patients. On the other hand we determined
the positive correlation between apoB and LDL2. ApoB
levels were significantly higher also in the presence of
IDL lipoproteins (IDL1: r = 0.386; p < 0.05: IDL2 r =
0.436; p < 0.01). AIP positively correlated with apoB too
(r = 0.422, P <0.01).
The relationships between selected groups of lipopro-
teins and TG in a group of patients with hypothyroidismTable 1 Characteristics of study participants
Group Hypothyroidism
Min-Max Average
Age, years 32-82 61.7 ± 1
BMI, kg/m2 19.61-37.78 27.19 ±
Smokers, n(%) 4 (10%)
Sex, F/M 36/4
BMI – Body Mass Index.are shown in Table 3. The presence of LDL3-7 is not
dependent on the TC and total LDL levels in patients
with hypothyroidism. There was a significantly positive
correlation between LDL3-7 and serum TG, LDL2, and
also with VLDL. IDL1 significantly positively correlated
with TG (r = 0.356, P < 0.01). Conversely HDL positively
correlated with serum non-atherogenic lipoproteins such
as LDL1 and IDL3 (r = 0.461, P < 0.01). We also recorded
a positive correlation between TG levels and BMI in our
study (r = 0.329, p < 0.05).
Except for LDL3-7, thyroid function parameters were
also identified as nonparametric data. We didn’t found
any correlation relationship between TSH and LDL3-7
(ρ = −0.069, NS) or between fT4 and LDL3-7 (ρ =
−0.153, NS) using Spearman correlation coeficient.
The effects of treatment on lipoprotein subfractions
The comparison of the data at the time of diagnosis and
after induction of euthyreosis was made by Student’s
paired t-test. For non-parametric data we then used Wil-
coxon signed-rank test. Input and after treatment values
for thyroid function parameters, lipid, apolipoprotein
levels, apoA1/apoB, AIP and lipoprotein subclasses for
hypothyroid patients are shown in Table 4.
Thyroxine substitution significantly reduced serum
lipids, except HDL. All patients had a phenotype A inHyperthyroidism
± SD Min-Max Average ± SD
2.03 28-58 43.9 ± 9.26
4.1 19.66- 30.86 24.68 ± 3.51
5 (16.67%)
25/5
Table 2 Correlations between subpopulations of LDL,
VLDL and HDL compared with AIP, apoB and apoA1/apoB
ratio in a group of patients with hypothyroidism
AIP apoB apoA1/apoB
r/ρ
Total LDL 0.169(NS) 0.706** −0.431**
LDL 1 −0.186(NS) 0.264(NS) −0.049(NS)
LDL 2 0.211(NS) 0.646** −0.482**
LDL 3-7 0.538** 0.570** −0.635**
VLDL 0.545** 0.571** −0.329*
HDL −0.491** 0.111(NS) 0.543**
r/ρ: r - Pearson’s ev. ρ - Spearman’s correlation coefficient.
(** = P <0.01, * = p <0.05, NS = not significant).
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cantly decreased serum levels of apolipoprotein B. There
was a significant reduction in AIP and no significant
change in values of apoA1/apoB ratio. Levels of LDL3-7
was significantly reduced in euthyreosis as well as were
the other lipoprotein subpopulations (Table 4, Figure 2).
On the other hand, there was a significant increase in
LDL1 levels. An important finding was the after-treatment
identification of the hyper-beta-lipoproteinemia with LDL
1,2 non-atherogenic lipoprotein profile, phenotype A (30%
of subjects). This type of lipoprotein spectrum was found
also prior to thyroxine substitution (15%). Even if the pa-
tient with hypothyroidism had no atherogenic lipoprotein
spectrum, also in this case the medical thyroid therapy
decreased individual levels of lipoproteins.
Input and after treatment values for thyroid function pa-
rameters, lipids, apolipoprotein levels, apoA1/apoB ratio,
AIP and lipoprotein subclasses for hyperthyroid patients
are shown in Table 5, Figure 3. Suppressive therapy for
thyroid significantly elevated levels of serum lipids and in-
dividual lipoprotein subclasses. This treatment also signifi-
cantly increased levels of apolipoproteins. Their ratio
(apoA1/apoB) was significantly reduced. There was not a
significant increase in AIP values. In euthyroid state TG
levels, LDL and HDL cholesterol were also in the refer-
ence range. There was only a light increase in TC levels.Table 3 Relationships between selected groups of
lipoproteins in a group of patients with hypothyroidism
VLDL LDL1 LDL2 LDL3-7
r/ρ
TC 0.572** 0.640** 0.608** 0.311(NS)
LDL 0.362* 0.698** 0.701** 0.294(NS)
HDL 0.008 (NS) 0.441** −0.091 (NS) −0.367*
TAG 0.561** 0.111 (NS) 0.270 (NS) 0.464**
LDL 3-7 0.342* −0.186(NS) 0.627** -
r/ρ: r - Pearson’s ev. ρ - Spearman’s correlation coefficient.
(** = P <0.01, * = p <0.05, NS = not significant).The average value of TC was slightly higher than the upper
limit of the reference range (5.571 ± 1.079 mmol/l). Also in
euthyreosis all patients had phenotype A and there were
16.67% of participants with hyper-beta-lipoproteinemia
with LDL 1,2 non-atherogenic lipoprotein profile, pheno-
type A.
Discussion
Cardiovascular diseases (CVD) remain the major cause of
morbidity and mortality in the world. Atherogenic dyslipo-
proteinemia which is involved in the formation of either
macro- or microvascular changes is now considered as the
most important risk factor for atherosclerotic changes devel-
opment [36-41]. An association betwen hypothyroidism and
coronary hearth disease (CHD) has been shown in many
epidemiological studies [42-46]. The induction of athero-
genic dislipidaemia seems to be a major component of the
association between hypothyroidism and CHD risk [19].
It is well known, that LDL represent a heterogeneous
group of particles which differ in size (22–27.2 nm),
density, cholesterol, and apoB conformation [1,3,4,7,36].
Nondenaturing gradient gel electrophoresis can identify
as many as seven distinct subspecies of LDL based on
density, that are grouped in four major subclasses LDL-
I-IV, from the largest, most buoyant to the smallest,
most dense particles [7]. In an alternative classification
based on particle diameter Austin et al. [47] suggested
two major patterns of LDL profile, pattern A (particle
diameter 25.5 nm or greater) and pattern B (particle
diameter less than 25.5 nm). It seems likely that LDL
atherogenicity increases continuously with decreasing
particle size and therefore that in this population small
LDLs will tent to be more atherogenic than large LDLs
[19]. Two phenotypes have been identified (i) phenotype
A comprising large, less dense LDL, present at low TG
levels; and (ii) phenotype B with abundant sdLDL
coupled with elevated TG and decreased HDL [7,19].
In our study we would like to point out to the identifi-
cation of the hyper-beta-lipoproteinemia, with LDL1, 2
non-atherogenic lipoprotein profile A. This type of lipo-
protein spectrum was found, either in a group of pa-
tients with hypothyroidism prior to treatment (15%) or
in some patients with euthyreosis after the treatment in
both groups (46.67%). LDL1 and LDL2 do not fulfil the
criteria of atherogenicity for lipoprotein entities which
are usually ascribed to LDL lipoproteins. Oravec et al.
reported, that LDL1 and LDL2 subfractions in hypercho-
lesterolemic indidviduals which created a non-
atherogenic hyper-betalipoproteinemia LDL1,2 without
the presence of atherogenic sdLDL were associated with
a high concentration of cardiovascular protective HDL
subfractions [48]. Although LDL2 particles are classified
as a large, buoyant LDL particles, their non-atherogenic
effect is possibly unclear. In our study we found positive
Table 4 Input and after treatment values for thyroid function parameters, lipid, apolipoprotein levels, apoA1/apoB
ratio, AIP and lipoprotein subclasses for hypothyroid patients
Hypothyroidism
Before treatment In euthyreosis
Average ±SD Min-Max Average ±SD Min-Max Signif.
TC (mmol/l) 6.10 ±1.56 2.6-9.2 5.45 ±1.03 3.26-7.27 **
TG (mmol/l) 2.05 ±1.62 0.7-10.1 1.29 ±0.55 0.48-2.5 ***
LDL (mmol/l) 3.86 ±1.25 1.6-6.4 3.38 ±0.85 1.89-5.33 **
HDL (mmol/l) 1.21 ±0.31 0.6-2 1.26 ±0.31 0.67-1.99 NS
apoA1(g/l) 1.89 ±0.65 0.87-3.47 1.67 ±0.40 0.77-2.6 *
apoB (g/l) 1.02 ±0.29 0.41-1.64 0.92 ±0.21 0.56-1.5 **
apoA1/apoB 1.95 ±0.71 0.87-3.44 1.86 ±0.5 1.16-2.88 NS
AIP 0.17 ±0.28 −0.31-0.95 −0.02 ±0.26 −0.38-0.47 ***
LDL1 (mg/dl) 47.35 ±18.48 10-113 53.78 ±15.33 32-87 *
LDL2 (mg/dl) 33.85 ±19.53 0-76 20.48 ±11.25 5-53 ***
IDL1 (mg/dl) 24.18 ±10.76 8-50 20.93 ±6.84 10-36 *
IDL2 (mg/dl) 15.78 ±6.88 4-30 13.35 ±3.87 8-21 *
IDL3 (mg/dl) 19.38 ±9.54 4-43 21.23 ±5.21 13-32 NS
VLDL (mg/dl) 40.03 ±16.84 8-80 31.20 ±9.58 10-61 ***
Not-normally distributed variables:
Median Q3-Q1 Min-Max Median Q3-Q1 Min-Max Signif.
TSH (mIU/l) 19.6 27.04 10.57-150 3.21 3,79 0.5-4.8 ***
fT4 (pmol/l) 7.24 3.17 1.56-9.0 15 3,41 12-21.8 ***
LDL3-7 (mg/dl) 6.5 10 0-54 0 1 0-8 ***
apo – apolipoprotein, AIP – atherogenic index of plasma, Q3-Q1 – interquartile range.
* significantly different via the Student’s t-test or Wilcoxon signed-rank test for non-parametric data: * p < 0.05; ** p < 0.01; *** p < 0.001
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apoB (Table 2, 3). On the other side Castelli published
evidence, that more than 75% of the patients with an
acute coronary syndrome or a myocardial infarction had
normal plasma values of LDL cholesterol or HDL chol-
esterol [49-51]. In our study we also identified normoli-
pemic patients with atherogenic lipoprotein profile. In
this cases, the methods enabling precise identification ofFigure 2 The Effect of treatment on LDL subfractions in
hypothyroid patients. (0) before treatment (1) in euthyreosis.atherogenic lipoprotein subpopulations with their clear
quantitation are reasonable and warranted.
We have also focused on the relationship between
plasma indicators of atherogenesis (Table 2). Results
shows significant positive correlation between AIP, apoB
and sdLDL (LDL3-7). ApoB were significantly higher not
only in the presence of elevated LDL3-7, but even in the
presence of LDL2 or IDL lipoproteins. ApoB100 is present
in all lipoprotein subclasses of LDL, VLDL, IDL, and also
Lp (a). ApoB levels provide an indirect information of par-
ticle density and size in those patients, where we can
assume an overgrowth of sdLDL [16]. Also other studies
indicate that elevated apoB are not necessarily directly
involved in sdLDL pathogenesis in hypothyroidism [19].
However, AIP (log TG/HDL-C) provides an information
about the lipoprotein profile in only one value. AIP allows
the prediction of the size of individual particles. Its value
significantly correlated with the size of LDL, HDL and
VLDL particles. It’s an indicator of atherogenic lipoprotein
phenotype (high risk >0.21; low risk < 0.11; intermediate
risk 0.11-0.21) [25,26]. There was positive correlation
between AIP adn LDL3-7 and also AIP and VLDL in our
study. For estimation of atherogenic lipoprotein profile
existence, an evaluation of the AIP seems to be better than
Table 5 Input and after treatment values for thyroid function parameters, lipid, apolipoprotein levels, apoA1/apoB
ratio, AIP and lipoprotein subclasses in hyperthyroid patients
Hyperthyroidism
Before treatment In euthyreosis
Average ±SD Min-Max Average ±SD Min-Max Signif.
TC (mmol/l) 3.65 ±0.62 2.9-5.0 5.57 ±1.08 2.77-6.9 ***
TG (mmol/l) 1.0 ±0.29 0.6-1.6 1.22 ±0.37 0.58-1.81 **
LDL (mmol/l) 2.05 ±0.42 1.47-3.21 3.26 ±0.77 1.34-4.29 ***
HDL (mmol/l) 1.03 ±0.22 0.67-1.45 1.38 ±0.26 0.93-2.17 ***
apoA1 (g/l) 1.56 ±0.29 1.10-2.09 1.92 ±0.25 1.52-2.6 ***
apoB (g/l) 0.61 ±0.12 0.42-0.99 0.92 ±0.17 0.42-1.15 ***
apoA1/apoB 2.59 ±0.55 1.90-3.76 2.16 ±0.49 1.58-3.79 ***
AIP −0.02 ±0.20 −0.33-0.32 −0.07 ±0.17 −0.50-0.18 NS
LDL1 (mg/dl) 35.97 ±8.29 25-60 53.80 ±10.75 25-69 ***
LDL2 (mg/dl) 7.00 ±2.42 2-12 15.67 ±10.17 3-36 ***
IDL1 (mg/dl) 11.93 ±2.53 6-17 17.33 ±5.38 8-26 ***
IDL2 (mg/dl) 8.90 ±2.58 5-14 12.17 ±3.87 4-18 ***
IDL3 (mg/dl) 15.47 ±4.97 7-27 26.63 ±8.27 5-42 ***
VLDL (mg/dl) 22.27 ±9.32 12-43 35.83 ±9.51 20-55 ***
Not-normally distributed variables:
Median Q3-Q1 Min-Max Median Q3-Q1 Min-Max Signif.
TSH (mIU/l) 0.001 0.0066 0.0025-0.054 2.1 2,22 0.5-4.9 ***
fT4 (pmol/l) 55.9 42,28 25.07-138 16.4 4,38 12.1-21.84 ***
LDL3-7 (mg/dl) 0 0 0 0 0 4 *
apo – apolipoprotein, AIP – atherogenic index of plasma, Q3-Q1 – interquartile range.
* significantly different via the Student’s t-test or Wilcoxon signed-rank test for non-parametric data: * p < 0.05; ** p < 0.01; *** p < 0.001.
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limitations in patients with familial hypercholesterolemia,
hypertriglyceridemia or chylomicronemia [52].
Relationship between TG levels as a resonable predictor
of LDL size phenotype category was documented in
several studies [19,47]. In this context, also in our study
phenotype B occurs more often in the case of combined
hyperlipidemia and hypertriglyceridemia than in isolated
hypercholesterolemia or in subjects with normal lipidFigure 3 The Effect of treatment on LDL subfractions in
hyperthyroid patients. (0) before treatment (1) in euthyreosis.levels. TG represent an important biomarker of CVD risk
becouse of their association with atherogenic remnant
particles and apoCIII, a proinflamatory, proatherogenic
protein found on all classes of the plasma lipoproteins.
Hypertriglyceridemic states are associated with increased
VLDL production and delayed VLDL clearance from cir-
culation [53-55]. Small dense LDL tend to be the rule with
triglycerides >1.5 mmol/l [11,19,56] and sdLDL particles
are usually found in association with high TG and low
HDL. The mechanism of this association could be ex-
plained by the increased of VLDL formation in elevated
TG levels, that result in TG enriched and cholesterol ester
depleted LDL particles (with effect of CEPT – cholesterol
ester transfer protein). Hepatic lipase than cleaves out the
TG leaving cholesterol ester depleted LDL [17] which are
physically smaller and becouse of resultant relative in-
crease in protein also denser [19]. This idea is also sup-
ported by the results in our study (Table 3). There was a
significantly positive correlation between LDL3-7 and
serum TG levels; and also between LDL3-7 and VLDL
levels. These findings remind us that hypertriglyceridemia
is one of the major cardiovascular risk factors, because of
the VLDL1 from which highly atherogenic LDL subfrac-
tions are formed, and may also be used to follow the
Minarikova et al. Lipids in Health and Disease 2014, 13:158 Page 8 of 10
http://www.lipidworld.com/content/13/1/158treatment. Association between hypertriglyceridemia levels
and documented coronary disease or strong correlation
with realtive risk for coronary artery disease (CAD) and
VLDL triglycerides, even contributions of elevated triglycer-
ides as an independent risk factor for cardiovascular disease
were documented in previous epidemiological studies
[50,57,58].
In context of hypothyroidism and atherogenic dyslipi-
daemia induction are shown contradictory results in the
literature. One study, focused on patients with overt
hypothyroidism [18], found no significant difference be-
tween the prevalence of phenotype B (predominance of
sdLDL) and a control group. According to other authors,
the size of LDL particles is not affected by the degree of
thyroid dysfunction and increased risk of atherosclerosis
in hypothyroidism is probably not related to the particle
size of LDL [20]. Another study was aimed to assess the
relationship between atherogenic dyslipidemia, sdLDL
and hypothyroidism. The results shown that underactive
thyroid gland affects the size of LDLs [19].
In our study we did not notice a positive correlation
between thyroid function parameters and the levels of
LDL3-7 although the prevalence of LDL3-7 (phenotype
B) was higher or only in hypothyroid subjects (52%),
than in patients with hyperthyroidism or in normal/
healthy population, which is reported to be about 31-
44% [47,59-61]. Although Abbas et al. study [19] alerts
that the short-term treatment of hypothyroidism is suffi-
cient to normalize quantitative lipid profiles, but not the
qualitative lipid profiles, it is possible that the latter may
need longer-term treatment with thyroxine to improve.
Our results have showed that substitution treatment
with levothyroxine (average dose 81.25 μg/day) during
7.13 months lead to an improvement of the lipid levels
as well as LDL subclasses and LDL 3–7 (Table 4). In
comparison to their treatment which lasted for a mean
15.7 weeks (range 6–40 weeks), in our study was the
average treatment 28.52 weeks (range 12–36). On the
other side, in our study was found a 30% prevalence of
hyper-beta-lipoproteinemia in euthyroid subjects after
thyreo-substitution. Probably this interval was also not
adequate to normalising lipid profiles, or it is typical
lipid profile for some subjects for their euthyroid state.
The effect of thyroid hormones on the composition of
lipoprotein spectrum and sdLDL occurence supports the
fact, that in the group of patients with hyperthyroidism,
LDL3-7 particles were not detected in any patient. Thyr-
eosuppresive treatment had the opposite effect on lipo-
protein levels but also without phenotype B presentation
in euthyreossis (Table 5).
Overall, we cannot say that either hyperthyroidism or
hypothyroidism is more favorable condition. There is an
incidence of adverse effects resulting from either increased
or underactive thyroid gland which can lead to highercardiovascular morbidity and mortality and also overall
morbidity. This has been shown in a several cross-
sectional and prospectively studies although they were not
completely uniform in its conclusions [62-64]. It only can
be said, that an alteration of thyroid function leads to
change in the lipid levels and lipoprotein subclasses and
thus to occurrence of sdLDL in hypothyreosis in our
examined group of patients, which was predominantly
consisted of postmenopausal women with elevated levels
of BMI. But in this context a substitution treatment of
subclinical hypothyroidism by levothyroxine may also be
helpful, taking into consideration the occurrence of
pro-atherogenic changes in the distribution of lipid [42].
Conclusion
The atherogenic lipoprotein profile was proved in 52.5%
of patients with hypothyroidism what presents a higher
prevalence than in normal or in age-related population.
Substitution treatment with levothyroxine leads to an im-
provement of the lipid levels, TG and as well as LDL sub-
classes. It significantly changed the presentation of sdLDL
in lipoprotein profiles – we noticed shift from the athero-
genic sdLDL to large, less atherogenic LDL particles.
SdLDL particles were not detected in any patient with
hyperthyroidism and thyreosuppresive treatment led to
significant rise in levels of lipid and lipoprotein sub-
classes. Non-atherogenic lipoprotein profile was present
in group of hyperthyroid patients before and also after
treatment.
Analysis of plasma atherogenesis markers: the levels of
small dense LDL particles correlated less ambiguous with
AIP than apoB levels; correlation between the amounts of
TC or LDLs and the presence of sdLDL was not recorded;
significantly positive correlation between the sdLDL and
TAG and sdLDL and VLDL alerts to hypertriglyceridemia
as a major cardiovascular risk factor.
We would like to point to the identification of the hyper-
beta-lipoproteinemia, with LDL1, 2 non-atherogenic lipo-
protein profile A among study participants.
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